Derivation of Huntington disease affected Genea020 human embryonic stem cell line  by Dumevska, Biljana et al.
Stem Cell Research 16 (2016) 430–433
Contents lists available at ScienceDirect
Stem Cell Research
j ourna l homepage: www.e lsev ie r .com/ locate /scrLab Resource: Stem Cell LineDerivation of Huntington disease affected Genea020 human embryonic
stem cell lineBiljana Dumevska ⁎, Teija Peura, Robert McKernan, Divya Goel, Uli Schmidt
Genea Biocells, Sydney, AustraliaN
In
P
C
D
O
T
S
K
A
Li
In
⁎ Corresponding author.
E-mail address: biljana.dumevska@geneabiocells.com
http://dx.doi.org/10.1016/j.scr.2016.02.009
1873-5061/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 26 January 2016
Accepted 1 February 2016
Available online 11 February 2016The Genea020 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying Htt gene CAG expansion of 48 repeats, indicative of Huntington disease. Following ICM out-
growth on inactivatedhuman feeders, karyotypewas conﬁrmed as46, XXbyCGHand STR analysis demonstrated
a female allele pattern. The hESC line had pluripotent cell morphology, 89% of cells expressed Nanog, 95% Oct4,
29% Tra1-60 and 99% SSEA4, gave a Pluritest pluripotency score of 27.51, novelty of 1.43 and demonstrated alka-
line phosphatase activity. The cell line was negative forMycoplasma and visible contamination.
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Cell line derivation
The embryo was plated whole onto mitomycin C inactivated human
feeders (Detroit 551 HFF, plated 130,000 cells 1 well of 4 wells —
68,421 cells/cm2) in 20% knock out serum in standard hESC culture
medium with 50 ng/ml Fgf2 (Amit et al., 2000). CGH karyotyping and
STR proﬁling were performed at the ﬁrst cryobanking step from ICM
outgrowths maintained on feeders. Alkaline phosphatase staining wastp://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Morphology and karyotype of Genea020. A) Brightﬁeld (passage 1) growing on
human inactivated feeders. B) Alkaline phosphatase activity (passage 21) on human
inactivated feeders. C) Karyotypic analysis (passage 5) showing 46, XY normal, male
karyotype.
Table 1
CGH analysis summary; Genea020 (passage 12, 3 enzymatic), reporting a female cell line
and no abnormalities detected.
CGH summary
Sample name Genea020 p12-TE3
Date reported 12th February 2013
Hybridisation balance Balanced hybridization was observed for all chromosomes
Copy number change No copy number changes above 400 kb were detected
Interpretation Female cell line
431B. Dumevska et al. / Stem Cell Research 16 (2016) 430–433performed on feeders. Cells were then enzymatically passaged as single
cells in M2 pluripotent cell maintenance medium (Genea Biocells) and
CGH/karyotyping repeated, immunoﬂuorescent pluripotent marker
staining, Pluritest, teratoma and sterility testing performed.Table 2
STR proﬁle; Genea020 (passage 29) demonstrating female allele pattern.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S317
SIVF-20 12,13 30,33.2 8 10 15 7,9 10,12Genetic analysis
1. Karyotyping: Passage 2; For enrichment of metaphase cells, cellular
outgrowths were incubated with either 0.22 ng/ml colcemid
(Invitrogen) and 37.5 g/ml BrdU (Sigma) for 17–19 h or 5 ng/ml
colcemid for 2.5 h. Single cells were subsequently obtained using
non-enzymatic cell dissociation solution (Sigma) and transferred to
Sydney IVF's (now Genea) diagnostic cytogenetics laboratory for
preparation of metaphase spreads and cytogenetic analysis by G-
banding. A minimum of 15 metaphase cells were examined, of
which a full karyotype or chromosome counts were performed for
5 and 10 of the metaphases respectively.
2. Comparative genomic hybridisation (CGH) based chromosomal
analysis: Passage 12 (9 on feeders, 3 enzymatic); CGH was used to
screen targeted regions of the genome for gains and losses associated
with chromosomal imbalances such as aneuploidy, deletions and
duplications. CGH was performed using SurePrint G3 microarrays
(8 × 60 K format) which were scanned with the Agilent Scanner C
and analysed using Genomic Workbench Standard Edition 5.0
software (Agilent Technologies).
3. DNA Proﬁling: Passage 29; DNA ‘ﬁngerprinting’was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the cell
lines. https://www.thermoﬁsher.com/order/catalog/product/4322288.
Pluripotency assessment
1. Alkaline Phosphatase: Passage 45; Genea020 grown on feeders were
stained as per manufacturer's protocol using the Merck Millipore
alkaline phosphatase detection kit (SCR004)
2. Immunoﬂuorescence: Passage 22 (19 on feeders, 3 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1-60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen:). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using In Cell Developer Software (GE).
3. Teratoma formation: Passage 42 (18 on feeders, 24 enzymatic); Two
CB17-SCID mice sourced from the Animal Resource Centre (ARC) in
Western Australia. Stem cells were received one day prior to injec-
tion and harvested using Collagenase IV treatment, washed in
DMEM/F12 and resuspended in injection buffer supplemented with
10% FBS and 30% BD Matrigel™. In both experiments, mice were
anaesthetised before intramuscular injection of the cells into the
hind leg of the mouse. Approximately 1×106 cells (1 × T25) in
50 μl were injected per mouse at one site only. Resultant teratomas
excised, ﬁxed, sectioned and stained for the assessment of tissues
from each of the embryonic germ layers.
4. Pluritest: Passage 12 (9 on feeders, 3 enzymatic); RNA was collected
and subjected to a Pluritest, a bioinformatic assay of pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012)
Sterility testing
1. Mycoplasma: Passage 12; testing was performed at the Victorian
Infectious Diseases Reference Laboratory using Mycoplasma genus
PCR
2. Microbial contamination: testing was performed in conjunction with
our QC measures. Cells were thawed and cultured in 7 ml antibiotic
free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal orD16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
11 24 13,16.2 14,17 8,11 14,15 11,12 19,20
Fig. 2.Pluripotency validation ofGenea020. A) Immunoﬂuorescent staining (10×)of pluripotent cellmarkers SSEA4 (green),Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 22, 3
enzymatic). B) Quantitation of expression of pluripotent markers. C) Pluritest pluripotency (left) and novelty (right) scores with Genea020 (passage 12, 3 enzymatic) outlined in black.
D) Tri-lineage teratoma formation (passage 42, 24 enzymatic) with (left) neuroepithelium, (middle) mesodermally derived stoma, cartilage, bone and (right) glandular epithelium.
432 B. Dumevska et al. / Stem Cell Research 16 (2016) 430–433yeast contamination. Clarity of the solution was assessed by Cell
Production Team.Veriﬁcation and authentication
Ethics/consents
Ethics approval for the project (‘the possibility that karyotyped em-
bryonic cells derived from non-viable “investigation” embryos could be
developed into stem cell lines’) was obtained from the Genea Ethics
Committee on 13 September 2005 under the Ethical Guidelines on the
Use of Assisted Reproductive Technology in Clinical Practice and Research
(ART guidelines, 2004) and the National Statement on Ethical Conduct
in Human Research. Karyotyped embryo cells were fully consented for
the development of stem cells by all responsible people through an
informed consent process (signed de-identiﬁed consent form can be
provided upon request). Donors have received no payment of other
beneﬁts for their donation. Donated embryos originally created by
assisted reproduction technology (ART) for the purpose of procreation.
Embryos were identiﬁed as unsuitable for implantation, biopsy or
freezing due to abnormal development. Embryonic outgrowths were
developed for consented clinical investigation studies. Results of the
studies have been reported back to the patient.PGD analysis conclusion
Mutation; expansion of CAG (17 and 48 CAG repeats) in HTT gene.
Family tree; embryo was de-identiﬁed. Huntington disease (HD) affect-
ed. See Bradley et al. (2011) for siblingship and sequencing analysis.Morphology
The derived stem cell line, Genea020, morphologically displays
adherent monolayer of compact cells in well-deﬁned colonies with
high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A, B).
Genetic analysis
The cell line has been karyotyped (Fig. 1C, Supplementary Fig. 1) and
also tested by CGH (Table 1, Supplementary Fig. 2), demonstrated 46,
XX karyotype, consistent with original derivation. Analysis of STR
markers showed allele pattern consistent with female genotype
(Table 2, Supplementary Fig. 3).
Pluripotency
GENEA020 is pluripotent by;
1. Alkaline phosphatase stain positivity (Fig. 1B)
2. Immunoﬂuorescence 89%Nanog positive, 95% Oct4, 29% Tra1-60 and
99% SSEA4 positive (Fig. 2A, quantiﬁed in Fig. 2B).
3. Pluritest with a pluripotency score of 27.51 and novelty score of 1.43
(Fig. 2C).
4. Teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 2D).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 4).
433B. Dumevska et al. / Stem Cell Research 16 (2016) 430–433Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.009.References
Amit, M., Carpenter, M.K., Inokuma, M.S., Chiu, C.P., Harris, C.P., Waknitz, M. a, ... Thomson,
J. a, 2000. Clonally derived human embryonic stem cell lines maintain pluripotency
and proliferative potential for prolonged periods of culture. Dev. Biol. 227 (2),
271–278. http://dx.doi.org/10.1006/dbio.2000.9912.
Bradley, C.K., Chami, O., Peura, T.T., Bosman, A., Dumevska, B., Schmidt, U., Stojanov, T.,
2010. Derivation of three new human embryonic stem cell lines. Vitro Cellular & De-
velopmental Biology - Animal 46(3–4), pp. 294–299. http://dx.doi.org/10.1007/
s11626-010-9298-y.
Bradley, C.K., Scott, H.A., Chami, O., Peura, T.T., Dumevska, B., Schmidt, U., ... Al, B.E.T.,
2011. Derivation of Huntington disease-affected human embryonic stem cell lines.
Stem Cells Dev. 20 (3).Laurent, L.C., Nievergelt, C.M., Lynch, C., Fakunle, E., Harness, J.V., Schmidt, U., ... Loring, J.F.,
2010. Restricted ethnic diversity in human embryonic stem cell lines. Nat. Methods 7
(1), 5–6. http://dx.doi.org/10.1038/nmeth0110-6.
Laurent, L.C., Ulitsky, I., Slavin, I., Tran, H., Schork, A., Morey, R., ... Loring, J.F., 2011. Dynam-
ic changes in the copy number of pluripotency and cell proliferation genes in human
ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell 8 (1),
106–118. http://dx.doi.org/10.1016/j.stem.2010.12.003.
McQuade, L., Balachandran, A., 2014. Proteomics of Huntington disease-affected human
embryonic stem cells reveals an evolving pathology involving mitochondrial dys-
function and metabolic. J. Proteome Res. http://dx.doi.org/10.1021/pr500649m.
Müller, F.-J., Schuldt, B.M., Williams, R., Mason, D., Altun, G., Papapetrou, E., ... Loring, J.F.,
2012. A bioinformatic assay for pluripotency in human cells. Nat. Methods 8 (4),
315–317. http://dx.doi.org/10.1038/nmeth.1580.A.
Tay, Y., Peter, S., Rigoutsos, I., Barahona, P., Ahmed, S., Dröge, P., 2009. Insights into the
regulation of a common variant of HMGA2 associated with human height during em-
bryonic development. Stem Cell Rev. Rep. 5 (4), 328–333. http://dx.doi.org/10.1007/
s12015-009-9095-8.
